Dongchen Zhou
Wuhan, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
PARP Inhibitors plus Anlotinib as Bridging Therapy for Armored CAR-T Cells in Ovarian Cancer Enhances Infiltration and Antitumor Efficacy.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: March 25, 2026
Tumor cell-derived IFN spatially reprograms osteopontin-enriched macrophage niches to promote PARP inhibitor resistance.
Journal: The Journal of clinical investigation
Published: August 12, 2025
Phosphorylated IRF3 promotes GSDME-mediated pyroptosis through RIPK1/FADD/caspase-8 complex formation during mitotic arrest in ovarian cancer.
Journal: Cell communication and signaling : CCS
Published: March 20, 2025
Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors.
Journal: Cell
Published: January 18, 2023
Bepotastine Sensitizes Ovarian Cancer to PARP Inhibitors through Suppressing NF-κB-Triggered SASP in Cancer-Associated Fibroblasts.
Journal: Molecular cancer therapeutics
Published: June 28, 2022
Effectiveness and Safety of Niraparib as Neoadjuvant Therapy in Advanced Ovarian Cancer With Homologous Recombination Deficiency (NANT): Study Protocol for a Prospective, Multicenter, Exploratory, Phase 2, Single-Arm Study.
Journal: Frontiers in oncology
Published: January 11, 2022
Cyclin-Dependent Kinase Inhibitors Function as Potential Immune Regulators via Inducing Pyroptosis in Triple Negative Breast Cancer.
Journal: Frontiers in oncology
Published: November 23, 2021
TAGLN mediated stiffness-regulated ovarian cancer progression via RhoA/ROCK pathway.
Journal: Journal of experimental & clinical cancer research : CR
Published: May 28, 2021
PARP inhibitors promote stromal fibroblast activation by enhancing CCL5 autocrine signaling in ovarian cancer.
Journal: NPJ precision oncology
Published: August 24, 2020
Showing 1-10 of 10
Last Updated: 09/26/2026